A Comparison of Once-Daily Triamcinolone Acetonide Aqueous and Twice-Daily Beclomethasone Dipropionate Aqueous Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis
Abstract:Ragweed pollen is the most frequent cause of allergic rhinitis in the late summer–fall in North America. The objectives of this multicenter, randomized, single-blind study are to assess the efficacy and safety of triamcinolone acetonide aqueous (TAA AQ) and beclomethasone dipropionate aqueous (BDP) in the treatment of adult patients with seasonal ragweed-induced allergic rhinitis. Patient's self-assessment of comfort with medication and healthrelated quality of life were also assessed. A total of 152 patients were randomized to treatment with TAA AQ 200 g once daily in the morning (n = 75) or BDP twice-daily 336 g/day (n = 77).
Document Type: Original Article
Publication date: 2003-05-01
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites